NOTA Laboratories Completes Venture Capital Round Led by Pegasus Tech Ventures

0

The capital allows University of Michigan spin-out to develop life-saving nitric oxide therapies.

ANN ARBOUR, Mich., September 15, 2022 /PRNewswire/ — NOTA Laboratories, a development-stage company specializing in proprietary nitric oxide (NO) delivery systems to treat a wide variety of serious respiratory and inflammatory diseases, has just completed its second round of funding led by Pegasus Tech Ventures, a global venture capital firm based in Silicon Valley. This funding is in addition to the $4.3 million the Company has already obtained NIH awards for its nitric oxide production technologies.

NOTA has two patented platform technologies that generate NO “on demand” inexpensively. The company’s systems are compact and suitable for hospital, clinic and home/outpatient use. NOGEN by NOTA The system generates NO continuously for up to 6 months through the electrochemical reduction of nitrite, while the company’s LANOR The system uses light-activated chemistry to produce NO from a strip of film coated with a proprietary chemical blend. LANOR is also small, lightweight and can be battery operated, making it ideal for emergency and home use.

The biological importance of nitric oxide was not discovered until the 1980s and has since garnered enormous attention from biomedical researchers with over 20,000 publications and 400 clinical trials underway using NO for a range of applications. NO is produced in our sinuses, blood vessels, and other parts of the body where it acts as an antiviral, antibacterial, vasodilator, anti-inflammatory, and antithrombotic. It is a key part of the body’s immune response to infection. NOTA systems can be used to increase the body’s production of NO for potentially life-saving applications such as persistent pulmonary hypertension of the newborn (PPHN), reduction of systemic inflammatory response syndrome (SIRS) during and after cardiopulmonary bypass (PCB) surgery, for use in the treatment of respiratory and their associated inflammatory response, and for chronic obstructive pulmonary disease (COPD).

Malcolm KahnNOTA’s CEO said, “We are excited about the expansion of our relationship with Pegasus and the synergies their investment partners are bringing to the table.” Bill Reichertpartner of Pegasus Tech Ventures, said, “We are delighted with the progress the NOTA team has made towards a commercial product, and we are very excited about the potential to deliver NO in a wide range of disease indications using a safer, more cost-effective medical device.”

NOTA’s other proprietary NO delivery technologies, which are single-use, disposable infection-fighting products, including a sinus spray, a sachet that can be placed in a face mask, and two catheter products, have been spun off into a separately managed startup called NOxygen Therapeutics.

Pegasus Technology Companys is a Silicon Valley-based global venture capital firm with $2 billion in assets under management. Pegasus provides intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a premier venture capital investment approach, Pegasus also offers a unique venture capital-as-a-service (VCaaS) model for large global corporations looking to partner with cutting-edge technology startups. For more information on Pegasus, visit https://www.pegasustechventures.com.

Contact:

Malcolm KahnCEO
201-615-5766
[email protected]
www.notalabs.com

SOURCE NOTE Laboratories

Share.

About Author

Comments are closed.